Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
9.56
+0.10 (1.06%)
Aug 25, 2026, 12:43 PM EDT - Market open
Atara Biotherapeutics Employees
Atara Biotherapeutics had 10 employees as of June 30, 2026. The number of employees decreased by 28 or -73.68% compared to the same quarter last year.
Employees
10
Change
-28
Growth
-73.68%
Revenue / Employee
$619,400
Profits / Employee
-$1,668,800
Market Cap
95.96M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 10 | -28 | -73.68% |
| Mar 31, 2026 | 13 | -76 | -85.39% |
| Dec 31, 2025 | 14 | -139 | -90.85% |
| Sep 30, 2025 | 38 | -121 | -76.10% |
| Jun 30, 2025 | 38 | -127 | -76.97% |
| Mar 31, 2025 | 89 | -84 | -48.55% |
| Dec 31, 2024 | 153 | -72 | -32.00% |
| Sep 30, 2024 | 159 | -149 | -48.38% |
| Jun 30, 2024 | 165 | -152 | -47.95% |
| Mar 31, 2024 | 173 | -157 | -47.58% |
| Dec 31, 2023 | 225 | -109 | -32.63% |
| Sep 30, 2023 | 308 | -32 | -9.41% |
| Jun 30, 2023 | 317 | -117 | -26.96% |
| Mar 31, 2023 | 330 | -240 | -42.11% |
| Dec 31, 2022 | 334 | -244 | -42.21% |
| Sep 30, 2022 | 340 | -238 | -41.18% |
| Jun 30, 2022 | 434 | -124 | -22.22% |
| Mar 31, 2022 | 570 | 90 | 18.75% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Adicet Bio | 102 |
| Pelthos Therapeutics | 92 |
| Fortress Biotech | 78 |
| Acrivon Therapeutics | 76 |
| PolyPid | 75 |
| ImmuCell | 73 |
| Cognition Therapeutics | 14 |
| Rallybio | 7 |
ATRA News
- 8 days ago - Atara Biotherapeutics reports Q2 EPS (32c), consensus (32c) - TheFly
- 12 days ago - Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress - Business Wire
- 13 days ago - Atara Biotherapeutics Quarterly report: Q2 2026 - Filings
- 13 days ago - Atara Biotherapeutics Earnings release: Q2 2026 - Filings
- 2 months ago - Atara Biotherapeutics Announces Changes to Its Board of Directors - Business Wire
- 2 months ago - Quetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemia - GlobeNewsWire
- 2 months ago - Atara Biotherapeutics Transcript: AGM 2026 - Transcripts
- 3 months ago - Atara Biotherapeutics upgraded to Hold from Sell at Freedom Broker - TheFly